Skip to main content
. 2021 Oct 28;13(11):1806. doi: 10.3390/pharmaceutics13111806

Figure 9.

Figure 9

Schematic summary of the main desirable biological features of BIs and BMIs. (A) and (B) represent low immunogenicity of the BI or BMI, with low/absent cytokine release (A) and low antibody recognition (B). (C) Biocompatibility and cellular viability. (D) Cellular proliferation and differentiation. (E) The porosity of the BI and BMI allows for nutrients and gases diffusion throughout the 3D construct. (F) Construct biodegradability. It is worth highlighting that the degradation process must not result in the production of toxic metabolites.